🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. BPX-601

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 1 mab terminated

    1 trial

  2. Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)

    Boehringer Ingelheim

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 other active

    1 trial

  3. Bemarituzumab

    Prime Medicine

    Gastrointestinal Cancer

    phase 1 mab completed

    1 trial

  4. BioTTT001 injection

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Locally Advanced Breast Cancer (LABC)

    phase 1 mab terminated

    1 trial

  5. Biological/Vaccine: therapeutic autologous dendritic cells.

    LISATA THERAPEUTICS, INC.

    Kidney Cancer

    phase 1 mab terminated

    1 trial

  6. C-TIL051

    Nektar Therapeutics UK Limited

    Metastatic Non Small Cell Lung Cancer

    phase 1 mab terminated

    1 trial

  7. C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.

    Pfizer Australia Pty Ltd

    Non-muscle invasive bladder cancer (NMIBC)

    phase 1 other active

    1 trial

  8. CAN-2409 + valacyclovir

    Candel Therapeutics

    Lung Cancer

    phase 1 mab completed

    1 trial

  9. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  10. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  11. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Ovarian Cancer

    phase 1 mab active

    1 trial

  12. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial

  13. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  14. CEA protein antigen plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    Rectal Cancer

    phase 1 mab active

    1 trial

  15. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial

  16. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer

    phase 1 mab active

    1 trial

  17. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial

  18. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  19. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  20. CEP-11981 (kinase inhibitor)

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  21. CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

    The George Institute

    Patients with recurrent and/or metastatic solid cancer.

    phase 1 other active

    1 trial

  22. CLR 131

    Cellectar Biosciences

    Head and Neck Cancer

    phase 1 small molecule completed

    1 trial

  23. CMP-001

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  24. CPI-006

    Corvus Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources